Testing BMS-986368 against a placebo for multiple sclerosis spasticity
Explore this study →
There are 4 groups in this study. Groups A, B and C receive BMS-986368. Group D, the placebo group, receives Placebo.
Sites in Edmonton, Lévis and 4 more cities
- Phase 2
- 4 groups
- Sites in Edmonton, London and 4 more cities
- Recruiting
Official title: A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity
Multiple Sclerosis Spasticity · Celgene